194 related articles for article (PubMed ID: 17291571)
1. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
[TBL] [Abstract][Full Text] [Related]
3. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model.
Iijima M; Chaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):622-7. PubMed ID: 17229509
[TBL] [Abstract][Full Text] [Related]
4. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P
Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428
[TBL] [Abstract][Full Text] [Related]
5. Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization.
Iijima M; Chaki S
Pharmacol Biochem Behav; 2005 Dec; 82(4):652-7. PubMed ID: 16359723
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects.
Ramos Ade T; Homem KS; Suchecki D; Tufik S; Troncone LR
Behav Brain Res; 2014 May; 265():69-75. PubMed ID: 24569014
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
Overstreet DH; Griebel G
Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
[TBL] [Abstract][Full Text] [Related]
8. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
9. The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.
Urani A; Philbert J; Cohen C; Griebel G
Pharmacol Biochem Behav; 2011 May; 98(3):425-31. PubMed ID: 21356230
[TBL] [Abstract][Full Text] [Related]
10. Corticotropin-releasing factor modulates maternal separation-induced ultrasonic vocalization in rat pups via activation of CRF1 receptor.
Ise S; Nagano N; Okuda S; Ohta H
Brain Res; 2008 Oct; 1234():59-65. PubMed ID: 18703034
[TBL] [Abstract][Full Text] [Related]
11. Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice.
Amikishieva AV; Ilnitskaya SI; Nikolin VP; Popova NA
Exp Oncol; 2011 Sep; 33(3):126-9. PubMed ID: 21956463
[TBL] [Abstract][Full Text] [Related]
12. Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models.
Ramos AT; Troncone LR; Tufik S
Neuroendocrinology; 2006; 84(5):309-16. PubMed ID: 17135717
[TBL] [Abstract][Full Text] [Related]
13. Involvement of vasopressin 3 receptors in chronic psychological stress-induced visceral hyperalgesia in rats.
Bradesi S; Martinez V; Lao L; Larsson H; Mayer EA
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G302-9. PubMed ID: 19033533
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.
Overstreet DH; Keeney A; Hogg S
Eur J Pharmacol; 2004 May; 492(2-3):195-201. PubMed ID: 15178365
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
[TBL] [Abstract][Full Text] [Related]
16. Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety.
St-Denis Y; Di Fabio R; Bernasconi G; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Ghirlanda D; Marchionni C; Messina F; Micheli F; Pavone F; Pasquarello A; Sabbatini FM; Zampori MG; Arban R; Vitulli G
Bioorg Med Chem Lett; 2005 Aug; 15(16):3713-6. PubMed ID: 15946843
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory role of vasopressin through V1b receptors in hapten-induced experimental colitis in rodents: implication in IBD.
Ferrier L; Serradeil-Le Gal C; Schulte AM; Vasina V; Gaultier E; Schroedel S; Ursino MG; Chaumaz G; Pascal M; De Ponti F; Bueno L
Am J Physiol Gastrointest Liver Physiol; 2010 Dec; 299(6):G1298-307. PubMed ID: 20864658
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
[TBL] [Abstract][Full Text] [Related]
19. CRF
Verdouw PM; van Esterik JC; Peeters BW; Millan MJ; Groenink L
Pharmacol Biochem Behav; 2017 Mar; 154():11-19. PubMed ID: 28089628
[TBL] [Abstract][Full Text] [Related]
20. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.
Serradeil-Le Gal C; Derick S; Brossard G; Manning M; Simiand J; Gaillard R; Griebel G; Guillon G
Stress; 2003 Sep; 6(3):199-206. PubMed ID: 13129813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
